ASAnupam Sarma

Anupam Sarma

*This is an algorithmically generated author record based on publicly available information.

Anupam Sarma has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Himakshi Baruah

    Advanced Drug Delivery Laboratory, Department of Pharmaceutics, School of Pharmaceutical Sciences, Girijananda Chowdhury University, Guwahati, India

    5 shared publications
  • Debojeet Basak

    Advanced Drug Delivery Laboratory, Department of Pharmaceutics, School of Pharmaceutical Sciences, Girijananda Chowdhury University, Guwahati, India

    3 shared publications
  • Malay K. Das

    3 shared publications
  • Malay Kumar Das

    Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, India

    3 shared publications
  • Mridusmita Das

    Advanced Drug Delivery Laboratory, Department of Pharmaceutics, School of Pharmaceutical Sciences, Girijananda Chowdhury University, Guwahati, India

    3 shared publications
  • Tapash Chakraborty

    Advanced Drug Delivery Laboratory, Department of Pharmaceutics, School of Pharmaceutical Sciences, Girijananda Chowdhury University, Guwahati, India

    3 shared publications

Latest Publications

  • The interplay between gut microbiota and Alzheimer’s disease: mechanistic insights from dysbiosis to disease modulation

    by Kakali Das, Rupjan Khatun, Sanjana Begum, Koushik Bhattacharyya, Madhushree Datta, Dipankar Saha, Anupam Sarma, Prachi Mehta, Bhrigu Kumar Das

    Alzheimer’s disease (AD) is a chronic, progressive, neurodegenerative condition marked by memory loss and cognitive decline. It is characterized by neuropathological features such as amyloid plaque accumulation, neurofibrillary tangles of tau protein, and inflammatory changes in the brain. Recent research emphasizes how gut microbes influence the onset and progression of AD primarily through the gut-brain connection, a bidirectional communication system. The human gastrointestinal tract (GI) contains trillions of bacteria, primarily Bacteroidetes, Firmicutes, and Actinobacteria, which play vital roles in digestion, metabolic regulation, and immune modulation. However, factors such as diet, lifestyle, and environmental exposure can disrupt microbial balance, weaken intestinal barrier function, and initiate systemic inflammation. Such dysbiosis has been linked to defective regulation of the amyloid precursor protein (APP), leading to increased deposition of amyloidogenic peptides (Aβ). Moreover, the enteric nervous system, which expresses APP, may serve as an initial site of amyloid deposition, affecting gastrointestinal motility and inflammatory susceptibility. The gut microbiota also produces key bioactive compounds, including neurotransmitters such as serotonin, dopamine, acetylcholine, histamine, and gamma-aminobutyric acid (GABA), which influence the central nervous system (CNS) through neural, immune, and endocrine pathways. An imbalance in these neuroactive molecules may disrupt synaptic signaling and contribute to Alzheimer’s-related cognitive dysfunction. Therefore, improving our understanding of gut-brain communication may advance knowledge of AD development and support the creation of new therapies. This review highlights the strong association between intestinal microbes and Alzheimer’s pathogenesis, emphasizing microbiota modulation through probiotics, prebiotics, postbiotics, synbiotics, and antibiotics as potential therapeutic approaches, supported by emerging clinical trial evidence.

  • Development of Nose-to-Brain Targeted Cow Milk-Derived Exosomes for Enhanced Delivery of Curcumin to the Brain

    by Himakshi Baruah, Anupam Sarma, Mridusmita Das, Hrishikesh Sarma, Debojeet Basak, Bhrigu Kumar Das

  • Open Access

    Valorization of mango peel and seed for sustainable applications in healthcare and cosmeceuticals: a review

    by Himakshi Baruah, Bhrigu Kumar Das, Tapash Chakraborty, Ashis Kumar Goswami, Deepjyoti Goswami, Kunal Pathak, Anupam Sarma


  • Nose to Brain Delivery of Curcumin Loaded Therapeutic Nanostructures for Neurodegenerative Diseases

    by Rupsikha Kalita, Anupam Sarma, Himakshi Baruah, Asifa Zaman, Deepjyoti Goswami

    Neurodegenerative diseases are progressive disorders that damage and eventually kill neurons in the central nervous system (CNS). In recent years, various research has been done on reliable and effective treatment methods for the most common neurodegenerative diseases such as Parkinson's, Alzheimer, and Migraine diseases. Different neurodegenerative disorders such as Huntington's disease, Alzheimer's disease, Parkinson's disease, amyotrophic, Lewy body disease can be treated by curcumin, which is a strong antioxidant polyphenol with neuroprotective and anti‐amyloid properties. However, Blood‐brain barrier (BBB) and blood cerebrospinal fluid barrier restricts the permeation of curcumin to the brain leads poor distribution of the drug in brain tissue. The intranasal pathway holds promise for enhancing the treatment of CNS disorders since it bypasses the BBB and increases the brain bioavailability of drug. As nanotechnology continues to improve, research on the delivery of drug through intranasal route has grown significantly in last 10 years. Several nanocarriers have been developed such as nano‐emulsions, microspheres, dendrimers, liposomes, carbon‐based nanoformulation, and nanoparticles to deliver curcumin to the brain via intranasal route for the treatment of neurodegenerative diseases. This study provided a thorough analysis of several curcumin nano‐formulations used in intranasal pathway as a novel treatment for neurodegenerative diseases.


  • Dry Gels: Concept, Current Trends, and New Avenues in Drug Delivery and Biomedical Application

    by Mary Boruah, Anupam Sarma

    Gels are cross‐linked semisolid systems traditionally classified as hydrogels and organogels, widely used in drug delivery. Organogels (oleogels), composed of organic solvents like paraffin or isopropyl palmitate, often suffer from instability and a greasy texture, limiting their pharmaceutical use. Hydrogels, containing water as the main liquid phase, face challenges due to poor compatibility with hydrophobic drugs and low mechanical strength, affecting drug release and distribution. These limitations have led to the development of advanced dry gel systems such as aerogels, cryogels, and xerogels. Dry gels possess high porosity, large surface area, and tunable internal structures, enabling improved drug solubility, controlled release, and enhanced bioavailability. Their adaptability to various administration routes—oral, transdermal, nasal, and pulmonary—adds to their therapeutic value. Additionally, their biocompatibility and structural resemblance to biological tissues make them suitable for tissue engineering, wound healing, biosensing, and gene therapy. This review highlights the drug loading and release mechanisms of dry gels and critically evaluates existing challenges, including toxicity concerns and the need for long‐term safety studies. Overall, dry gels represent a promising class of biomaterials capable of advancing drug delivery and improving outcomes across a broad spectrum of biomedical applications.


  • Linalool in chronic diseases: A comprehensive review of its pharmacological potential and delivery aspects

    by Ashis Kumar Goswami, Anupam Sarma, Sahabuddin Ahmed, Bhrigu Kumar Das


  • Open Access

    Insight into central nervous system targeted nanostructured lipid carriers via the nose to brain pathway

    by Mridusmita Das, Anupam Sarma, Himakshi Baruah, Debojeet Basak

    In nanomedicine, targeting the central nervous system (CNS) is one of the biggest challenges. The presence of the blood–brain barrier (BBB) leads to the failure of drugs to reach the brain; hence, CNS-related diseases are challenging to treat. Various invasive and noninvasive methods have been established to overcome the difficulty of passing through the BBB. Delivery of drugs by using nanoparticles through the nasal route is one of the noninvasive methods developed to treat CNS disorders. The nose to brain pathway allows direct transport to the brain without crossing the BBB. Among the nanocarriers designed to target the CNS, nanostructured lipid carriers (NLC) are the focus of this review. NLCs appeared as a newer generation of solid lipid nanoparticles (SLN) developed to get over SLN's limitations. They are novel pharmaceutical preparations made of lipids, surfactants and co-surfactants that are physiologic and biocompatible. Liquid lipids (oil) are added to the solid lipid to create a matrix which results in structural flaws in the solid lipids and creates a less ordered crystalline framework that prevents leakage of the drug and provides high drug loading. The imperfection in the internal arrangement of NLCs aids more drug accommodation. A systematic search was performed across the main databases like PubMed, Springer, Scopus, Taylor and Francis, Google Scholar and Wiley. The search applied terms and keywords related to nose to brain delivery, nanostructured lipid carriers and neurodegenerative diseases. This review discusses the anatomy of the nose, associated pathways, advantages and limitations of NLCs, and preparation techniques and recent developments of NLCs delivered via the nose to brain route. The reported records demonstrated the feasibility and potential of NLCs for innovative uses for treatment in the future via the nose to brain route.


  • Exosome: From biology to drug delivery

    by Himakshi Baruah, Anupam Sarma, Debojeet Basak, Mridusmita Das

    In recent years, different advancements have been observed in nanosized drug delivery systems. Factors such as stability, safety and targeting efficiency cause hindrances in the clinical translation of these synthetic nanocarriers. Therefore, researchers employed endogenous nanocarriers like exosomes as drug delivery vehicles that have an inherent ability to target more efficiently after appropriate functionalization and show higher biocompatibility and less immunogenicity and facilitate penetration through the biological barriers more quickly than the other available carriers. Exosomes are biologically derived lipid bilayer-enclosed nanosized extracellular vesicles (size ranges from 30 to 150 nm) secreted from both prokaryotic and eukaryotic cells and appears significantly in the extracellular space. These EVs (extracellular vesicles) can exist in different sources, including mammals, plants and microorganisms. Different advanced techniques have been introduced for the isolation of exosomes to overcome the existing barriers present with conventional methods. Extensive research on the application of exosomes in therapeutic delivery for treating various diseases related to central nervous system, bone, cancer, skin, etc. has been employed. Several studies are on different stages of clinical trials, and many exosomes patents have been registered. Graphical abstract